The Centers for Disease Control and Prevention has released guidance on what to consider when evaluating adolescents for pre-exposure prophylaxis for the prevention of HIV.
Regenerating islet-derived protein 3α is a gut damage marker in inflammatory bowel diseases. Because people with HIV who are taking antiretroviral therapy often present with altered gut microbiota,...
Because diastolic dysfunction is common among individuals with HIV, authors of the CHART study aimed to evaluate the cardiovascular effects of dysfunction among patients receiving antiretroviral therapy. ...
By analyzing results of the multi-cohort Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study, researchers determined whether contemporary protease inhibitors have similar effects on chronic...
In a new study, the researchers aimed to compare antibody titers to HPV with the rate of abnormal cytology between perinatally HIV-infected and perinatally HIV-exposed, uninfected youth.
The FDA has approved a new option for HIV-1 pre-exposure prophylaxis to reduce HIV-1 infection risk from sex, excluding in those who have receptive vaginal sex.
In his session as IAS 2019, Myron Cohen, MD, discussed new long-acting injectables for HIV prevention and the ongoing trials that will determine the efficacy of each.
